David J Waxman Selected Research

Axitinib (AG 013736)

5/2013	Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
4/2011	Antiangiogenesis enhances intratumoral drug retention.
1/2009	Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
1/2008	Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David J Waxman Research Topics

Disease

45	Neoplasms (Cancer) 01/2022 - 01/2002
8	Glioma (Gliomas) 01/2020 - 06/2014
7	Gliosarcoma 02/2013 - 01/2003
6	Hypersensitivity (Allergy) 01/2018 - 12/2010
5	Brain Neoplasms (Brain Tumor) 05/2015 - 03/2012
4	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2006
4	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 07/2004
4	Hypoxia (Hypoxemia) 05/2015 - 08/2005
4	Prostatic Neoplasms (Prostate Cancer) 11/2011 - 01/2009
3	Feminization 01/2022 - 01/2016
3	Inflammation (Inflammations) 11/2020 - 12/2010
3	Liver Neoplasms (Liver Cancer) 01/2016 - 07/2002
2	Liver Diseases (Liver Disease) 01/2022 - 01/2016
2	Disease Susceptibility (Diathesis) 01/2020 - 11/2015
2	Carcinogenesis 06/2019 - 03/2007
2	Obesity 01/2019 - 01/2016
2	Melanoma (Melanoma, Malignant) 11/2016 - 04/2016
2	Infections 01/2016 - 12/2008
2	Neoplasm Metastasis (Metastasis) 04/2013 - 04/2010
2	Starvation 01/2009 - 12/2008
1	Fibrosis (Cirrhosis) 01/2020
1	Insulin Resistance 01/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2016
1	Carcinoma (Carcinomatosis) 11/2016

Drug/Important Bio-Agent (IBA)

28	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
25	Pharmaceutical PreparationsIBA 01/2021 - 01/2002
18	ProdrugsIBA 01/2014 - 01/2002
12	EnzymesIBA 01/2017 - 01/2002
11	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 04/2011 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2003
7	ChromatinIBA 01/2022 - 01/2011
7	Angiogenesis InhibitorsIBA 01/2021 - 11/2007
7	CytochromesIBA 09/2010 - 01/2003
6	Deoxyribonucleases (DNase)FDA Link 01/2018 - 12/2010
6	Ifosfamide FDA LinkGeneric 02/2007 - 01/2002
5	Growth Hormone (Somatotropin)IBA 01/2019 - 12/2010
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2014 - 01/2009
4	Axitinib (AG 013736)IBA 05/2013 - 01/2008
3	Therapeutic UsesIBA 01/2022 - 01/2002
3	XenobioticsIBA 06/2019 - 01/2016
3	CytokinesIBA 11/2016 - 03/2012
3	LipidsIBA 01/2016 - 01/2011
3	PPAR alphaIBA 01/2016 - 07/2002
3	ChemokinesIBA 05/2015 - 03/2012
3	Cytochrome P-450 CYP2B1 (PROD)IBA 12/2010 - 09/2005
3	CaspasesIBA 09/2010 - 12/2002
3	Oxidoreductases (Dehydrogenase)IBA 03/2006 - 01/2002
3	Cytochrome P-450 CYP3AIBA 09/2005 - 01/2003
3	AnthracyclinesIBA 08/2005 - 01/2003
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
2	InterferonsIBA 01/2020 - 05/2015
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 06/2019 - 07/2002
2	Insulin (Novolin)FDA Link 01/2019 - 09/2008
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2018 - 09/2010
2	1,4- bis(2- (3,5- dichloropyridyloxy))benzeneIBA 01/2018 - 01/2017
2	PPAR gammaIBA 01/2016 - 09/2008
2	Transcription Factors (Transcription Factor)IBA 01/2016 - 03/2010
2	Complement System Proteins (Complement)IBA 05/2015 - 12/2010
2	Sorafenib (BAY 43-9006)FDA Link 06/2014 - 05/2013
2	Oxygen (Dioxygen)IBA 05/2013 - 04/2011
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2013 - 12/2008
2	DNA (Deoxyribonucleic Acid)IBA 01/2013 - 12/2008
2	Tyrosine Kinase InhibitorsIBA 04/2011 - 01/2009
2	4-hydroxycyclophosphamideIBA 04/2011 - 01/2009
2	methyl cellosolve (ethylene glycol monomethyl ether)IBA 03/2011 - 06/2010
2	methoxyacetic acidIBA 03/2011 - 06/2010
2	Biological ProductsIBA 01/2011 - 04/2010
2	AndrogensIBA 12/2010 - 04/2010
2	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 09/2010 - 09/2005
2	Glutathione (Reduced Glutathione)IBA 08/2005 - 12/2002
2	methoxy-morpholinyl-doxorubicinIBA 01/2005 - 01/2003
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Contrast MediaIBA 01/2021
1	VaccinesIBA 01/2020
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Interferon Type IIBA 01/2020
1	SteroidsIBA 06/2019
1	STAT5 Transcription FactorIBA 01/2019
1	AdiponectinIBA 01/2019
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2019
1	Insulin ReceptorIBA 01/2019
1	Fibroblast Growth Factor 1 (FGF-1)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Insulin Receptor Substrate ProteinsIBA 01/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2019
1	Cytotoxins (Cytolysins)IBA 10/2018
1	Polystyrenes (Polystyrene)IBA 10/2018
1	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2018
1	Cyclin D1IBA 01/2017
1	Constitutive Androstane ReceptorIBA 01/2017
1	CateninsIBA 01/2017
1	Cytokine Receptors (Cytokine Receptor)IBA 11/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2016
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 11/2016
1	CpG ODN 1826IBA 04/2016

Therapy/Procedure

23	Therapeutics 01/2022 - 01/2002
16	Drug Therapy (Chemotherapy) 01/2022 - 12/2003
2	Caloric Restriction 11/2020 - 01/2016
1	Immunotherapy 04/2016